0000950170-24-069310.txt : 20240605 0000950170-24-069310.hdr.sgml : 20240605 20240605161007 ACCESSION NUMBER: 0000950170-24-069310 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dunn Edmund CENTRAL INDEX KEY: 0001989401 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 241022086 MAIL ADDRESS: STREET 1: MONTE ROSA THERAPEUTICS, INC. STREET 2: 321 HARRISON AVENUE, SUITE 900 CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 4 1 ownership.xml 4 X0508 4 2024-06-03 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001989401 Dunn Edmund MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900 BOSTON MA 02118 false true false false Principal Accounting Officer false Common Stock 2024-06-03 4 S false 1207 4.0396 D 15554 D Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.0111 to $4.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Phil Nickson, Attorney-in-Fact 2024-06-05